Be the first person to write a business review for CytoGenix, Inc.

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

Cytori Therapeutics, Inc. company was founded in 1996 and is headquartered in San Diego, California. Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a development stage pharmaceutical company that acquires therapeutic molecules and medical technologies from third parties, and advances their clinical development for later sale to pharmaceutical and biotechnology companies. DARA focuses on two drug development programs: KRN5500 for neuropathic pain in cancer patients and DB959 for type 2 diabetes. On February 12, 2008, Point and DARA BioSciences, Inc. completed their merger transaction, in which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with and into DARA BioSciences, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.